

# Adaptimmune to Present Two Trials in Progress Posters at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

PHILADELPHIA and OXFORD, U.K., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, today announced that it will present two trials in progress posters at the 2017 SITC annual meeting November 8-12, 2017 at the Gaylord National Hotel & Convention Center in National Harbor, Maryland, United States.

In addition, Adaptimmune will have a corporate exhibition booth (#718), and the company will also be hosting a dinner for investors on November 10<sup>th</sup> with representatives from Adaptimmune's leadership team and key opinion leader Dr. David S. Hong from The University of Texas MD Anderson Cancer Center. Please reach out to Adaptimmune Investor Relations ([juli.miller@adaptimmune.com](mailto:juli.miller@adaptimmune.com)) for more information on attending the dinner.

The trials in progress posters will summarize the study designs for Adaptimmune's ongoing MAGE-A4 multi-tumor study in urothelial ("bladder"), melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, and gastric cancers; and, the combination study with NY-ESO and NY-ESO and KEYTRUDA® (pembrolizumab) in multiple myeloma. Details are below.

## *Trials in Progress Posters:*

- **Title:** Study Design: Phase 1 dose escalation, multi-tumor study to assess safety, tolerability and antitumor activity of genetically engineered MAGE-A4 SPEAR T-cells in HLA-A2<sup>+</sup> subjects with MAGE-A4<sup>+</sup> tumors
  - **Poster Number:** P247
  - **Session Time:** November 10, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 PM (reception)
  - **Location:** Prince George's Exhibition Hall DE
- **Title:** Study Design: An Open-label Randomized Pilot Study of NY-ESO-1 SPEAR T-cells Alone or in Combination with Pembrolizumab in HLA-A2<sup>+</sup> Subjects with Relapsed and Refractory Multiple Myeloma (NCT03168438)
  - **Poster Number:** P248
  - **Session Time:** November 11, 2017 from 12:30 PM to 2:00 PM (lunch) and 6:30 PM to 8:00 PM (reception)

## About Adaptimmune

Adaptimmune is a clinical-stage biopharmaceutical company focused on the development of novel cancer immunotherapy products. The Company's unique SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. Adaptimmune is currently conducting clinical trials with SPEAR T-cells targeting MAGE-A4, -A10, and AFP across several solid tumor indications. GlaxoSmithKline plc (LSE:GSK) (NYSE:GSK) exercised its option to exclusively license the right to research, develop, and commercialize Adaptimmune's NY-ESO SPEAR T-cell therapy program in September 2017. Transition of this program to GSK is ongoing. The Company is located in Philadelphia, USA and Oxfordshire, U.K. For more information, please visit <http://www.adaptimmune.com>

### **Forward-Looking Statements**

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (PSLRA). These forward-looking statements involve certain risks and uncertainties. Such risks and uncertainties could cause our actual results to differ materially from those indicated by such forward-looking statements, and include, without limitation: the success, cost and timing of our product development activities and clinical trials and our ability to successfully advance our TCR therapeutic candidates through the regulatory and commercialization processes. For a further description of the risks and uncertainties that could cause our actual results to differ materially from those expressed in these forward-looking statements, as well as risks relating to our business in general, we refer you to our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (SEC) on November 2, 2017, and our other SEC filings. The forward-looking statements contained in this press release speak only as of the date the statements were made and we do not undertake any obligation to update such forward-looking statements to reflect subsequent events or circumstances.

### **Adaptimmune Contacts Investor Relations**

Juli P. Miller, Ph.D.

T: (215) 825-9310

E: [juli.miller@adaptimmune.com](mailto:juli.miller@adaptimmune.com)

### **Media Relations**

Margaret Henry

T: +44 (0)1235 430036

Cell: +44 (0)7710 304249

E: [margaret.henry@adaptimmune.com](mailto:margaret.henry@adaptimmune.com)

Source: Adaptimmune Therapeutics plc